Head to Head Contrast: Coya Therapeutics (COYA) vs. Its Competitors

Coya Therapeutics (NASDAQ:COYA) is one of 847 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Coya Therapeutics to similar companies based on the strength of its earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Risk & Volatility

Coya Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Coya Therapeutics’ competitors have a beta of 1.07, meaning that their average share price is 7% more volatile than the S&P 500.

Valuation and Earnings

This table compares Coya Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coya Therapeutics	$8.02 million	-$21.23 million	-3.79
Coya Therapeutics Competitors	$695.88 million	$9.64 million	-10.01

Coya Therapeutics’ competitors have higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Coya Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1	0	6	0	2.71
Coya Therapeutics Competitors	9766	15001	45311	1578	2.54

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 277.67%. As a group, “Biotechnology” companies have a potential upside of 90.51%. Given Coya Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Coya Therapeutics is more favorable than its competitors.

Profitability

This table compares Coya Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Coya Therapeutics Competitors	-9,046.42%	-198.98%	-30.68%

Summary

Coya Therapeutics competitors beat Coya Therapeutics on 7 of the 13 factors compared.

About Coya Therapeutics

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.